Cosmo Pharmaceuticals Announces Cassiopea’s Very Positive Top-Line Phase 3 Results for Winlevi® (Clascoterone) in Treating Acne
Cosmo Pharmaceuticals N.V. today announced that Cassiopea, a clinical-stage specialty pharmaceutical company focused on developing medical dermatology products of which Cosmo holds a 45% stake, today announced that top line results from two pivotal phase 3 clinical trials for its topical anti-androgen Winlevi® (Clascoterone) demonstrated highly statistically significant improvements for all primary clinical end points.